Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.0902 EUR
29.83 M EUR
468.06 M EUR
253.12 M
About TELIX PHARMACEUTICALS LIMITED
Sector
Industry
CEO
Christian P. Behrenbruch
Website
Headquarters
Melbourne
Founded
2017
ISIN
AU000000TLX2
FIGI
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Telix Pharmaceuticals Limited stocks are traded under the ticker A2H7JK.
A2H7JK stock has fallen by −0.10% compared to the previous week, the month change is a −0.10% fall, over the last year Telix Pharmaceuticals Limited has showed a −0.10% decrease.
We've gathered analysts' opinions on Telix Pharmaceuticals Limited future price: according to them, A2H7JK price has a max estimate of 21.87 EUR and a min estimate of 17.71 EUR. Watch A2H7JK chart and read a more detailed Telix Pharmaceuticals Limited stock forecast: see what analysts think of Telix Pharmaceuticals Limited and suggest that you do with its stocks.
A2H7JK stock is 1.45% volatile and has beta coefficient of 0.74. Track Telix Pharmaceuticals Limited stock price on the chart and check out the list of the most volatile stocks — is Telix Pharmaceuticals Limited there?
Yes, you can track Telix Pharmaceuticals Limited financials in yearly and quarterly reports right on TradingView.
Telix Pharmaceuticals Limited is going to release the next earnings report on Aug 21, 2025. Keep track of upcoming events with our Earnings Calendar.
Telix Pharmaceuticals Limited revenue for the last quarter amounts to 105.76 M EUR, despite the estimated figure of 105.76 M EUR. In the next quarter, revenue is expected to reach 326.85 M EUR.
A2H7JK net income for the last half-year is 12.11 M EUR, while the previous report showed 18.45 M EUR of net income which accounts for −34.38% change. Track more Telix Pharmaceuticals Limited financial stats to get the full picture.
No, A2H7JK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Telix Pharmaceuticals Limited EBITDA is 48.96 M EUR, and current EBITDA margin is 11.52%. See more stats in Telix Pharmaceuticals Limited financial statements.
Like other stocks, A2H7JK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Telix Pharmaceuticals Limited stock right from TradingView charts — choose your broker and connect to your account.